<DOC>
	<DOCNO>NCT00941148</DOCNO>
	<brief_summary>The aim study show treatment Glargine lead improvement beta cell function especially within time maximal beta cell stress occur meal . For reason three different standardize test meal ( breakfast , lunch , dinner ) perform postprandial secretion intact proinsulin level measure . These measurement perform patient treat combination metformin insulin glargine versus metformin plus NPH insulin ( within core study ) significant difference observe , third treatment arm metformin plus insulin detemir . Hypothesis area curve ( AUC ) intact proinsulin level within 2 hour test meal dinner metformin plus insulin glargin differs AUC intact proinsulin level metformin plus NPH insulin .</brief_summary>
	<brief_title>Beta-Cell Function Insulin Glargine Compared Neutral Protamine Hagedorn ( NPH ) Insuline Insulin Detemir Combination With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<criteria>Type 2 Diabetes mellitus accord ADA criterion HbA1c 6.5 % 8.5 % Individually optimize combination therapy metformin combination sulfonylurea stable dosage within last 3 month Age 40 75 year Fasting intact proinsulin level &gt; 7 pmol/Land &lt; 20 pmol/Lat screen Type 1 Diabetes mellitus PreTreatment insulin within last 3 month prior screen PreTreatment PPARyagonists ( glitazones ) within last 3 month prior screen Major micro macrovascular complication judge investigator BMI &gt; 40 kg/mÂ² Hypokalemia ( K &lt; 3.5 mmol /L ) History drug alcohol abuse Anamnestic history hypersensitivity study drug drug similar chemical structure History severe multiple allergy Treatment investigational drug within 3 month prior screen Progressive fatal disease History significant cardiovascular , respiratory , gastrointestinal , hepatic ( ALAT and/or ASAT &gt; 3 time normal reference range ) , renal ( creatinine &gt; 1.3 mg/dL woman &gt; 1.7 mg/dL men ) , neurological , psychiatric and/or haematological disease judge investigator Pregnancy breast feed Sexually active woman childbearing potential actively consistently practice birth control use medically accept device therapy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>